Mobile phone text messaging for medication adherence in secondary prevention of cardiovascular disease
Julie Redfern,Qiang Tu,Karice Hyun,Matthew A Hollings,Nashid Hafiz,Clara Zwack,Caroline Free,Pablo Perel,Clara K Chow
DOI: https://doi.org/10.1002/14651858.cd011851.pub3
IF: 8.4
2024-03-28
Cochrane Database of Systematic Reviews
Abstract:Cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for almost 18 million deaths annually. People with CVDs have a five times greater chance of suffering a recurrent cardiovascular event than people without known CVDs. Although drug interventions have been shown to be cost‐effective in reducing the risk of recurrent cardiovascular events, adherence to medication remains suboptimal. As a scalable and cost‐effective approach, mobile phone text messaging presents an opportunity to convey health information, deliver electronic reminders, and encourage behaviour change. However, it is uncertain whether text messaging can improve medication adherence and clinical outcomes. This is an update of a Cochrane review published in 2017. To evaluate the benefits and harms of mobile phone text messaging for improving medication adherence in people with CVDs compared to usual care. We searched CENTRAL, MEDLINE, Embase, four other databases, and two trial registers. We also checked the reference lists of all primary included studies and relevant systematic reviews and meta‐analyses. The date of the latest search was 30 August 2023. We included randomised controlled trials (RCTs) with participants with established arterial occlusive events. We included trials investigating interventions using short message service (SMS) or multimedia messaging service (MMS) with the aim of improving adherence to medication for the secondary prevention of cardiovascular events. The comparator was usual care. We excluded cluster‐RCTs and quasi‐RCTs. We used standard Cochrane methods. Our primary outcomes were medication adherence, fatal cardiovascular events, non‐fatal cardiovascular events, and combined CVD event. Secondary outcomes were low‐density lipoprotein cholesterol for the effect of statins, blood pressure for antihypertensive drugs, heart rate for the effect of beta‐blockers, urinary 11‐dehydrothromboxane B2 for the antiplatelet effects of aspirin, adverse effects, and patient‐reported experience. We used GRADE to assess the certainty of the evidence for each outcome. We included 18 RCTs involving a total of 8136 participants with CVDs. We identified 11 new studies in the review update and seven studies in the previous version of the review. Participants had various CVDs including acute coronary syndrome, coronary heart disease, stroke, myocardial infarction, and angina. All studies were conducted in middle‐ and high‐income countries, with no studies conducted in low‐income countries. The mean age of participants was 53 to 64 years. Participants were recruited from hospitals or cardiac rehabilitation facilities. Follow‐up ranged from one to 12 months. There was variation in the characteristics of text messages amongst studies (e.g. delivery method, frequency, theoretical grounding, content used, personalisation, and directionality). The content of text messages varied across studies, but generally included medication reminders and healthy lifestyle information such as diet, physical activity, and weight loss. Text messages offered advice, motivation, social support, and health education to promote behaviour changes and regular medication‐taking. We assessed risk of bias for all studies as high, as all studies had at least one domain at unclear or high risk of bias. Medication adherence Due to different evaluation score systems and inconsistent definitions applied for the measurement of medication adherence, we did not conduct meta‐analysis for medication adherence. Ten out of 18 studies showed a beneficial effect of mobile phone text messaging for medication adherence compared to usual care, whereas the other eight studies showed either a reduction or no difference in medication adherence with text messaging compared to usual care. Overall, the evidence is very uncertain about the effects of mobile phone text messaging for medication adherence when compared to usual care. Fatal cardiovascular events Text messaging may have little to no effect on fatal cardiovascular events compared to usual care (odds ratio 0.83, 95% confidence interval (CI) 0.47 to 1.45; 4 studies, 1654 participants; low‐certainty evidence). Non‐fatal cardiovascular events We found very low‐certainty evidence that text messaging may have little to no effect on non‐fatal cardiovascular events. Two studies reported non‐fatal cardiovascular events, neither of which found evidence of a difference between groups. Combined CVD events We found very low‐certainty evidence that text messaging may have little to no effect on combined CVD events. Only one study reported combined CVD events, and did not find evidence of a difference between groups. Low‐density lipoprotein cholesterol Text messaging may have little to no effect on low‐density lipoprotein cholesterol compared to usual care (mean difference (MD) −1.79 mg/dL, 95% CI −4.71 to 1.12; 8 st -Abstract Truncated-
medicine, general & internal